Alliancebernstein L.P. Aligos Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

  • $290 Billion
  • Q2 2025

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 06, 2021
SELL
$19.1 - $34.94 $955,000 - $1.75 Million
-50,000 Closed
0 $0
Q4 2020

Feb 08, 2021
BUY
$13.2 - $32.74 $660,000 - $1.64 Million
50,000 New
50,000 $1.38 Million

Others Institutions Holding ALGS

# of Institutions
1
Shares Held
227K
Call Options Held
0
Put Options Held
0
View Full List

About Aligos Therapeutics, Inc.

ALGS Quotes by TradingView
  • Ticker ALGS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,717,000
  • Market Cap $331M
  • Description
  • Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...
More about ALGS
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email